{
    "clinical_study": {
        "@rank": "45207", 
        "arm_group": [
            {
                "arm_group_label": "Phase Ib", 
                "arm_group_type": "Experimental", 
                "description": "To estimate the safe dose of the combination INC280 and buparlisib"
            }, 
            {
                "arm_group_label": "Phase II", 
                "arm_group_type": "Experimental", 
                "description": "To estimate anti-tumor efficaty of the combination INC280 and buparlisib"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will assess the safety and the dose of the combination of INC280 and buparlisib\n      (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent\n      glioblastoma  with PTEN mutations, homozygous deletion of PTEN or PTEN negative by IHC."
        }, 
        "brief_title": "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Deletion of PTEN or PTEN Negative by IHC, INC280, BKM120, Buparlisib; Recurrent Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part is to\n      estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination\n      of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy and\n      to further assess the safety of the combination. A maximum of 10 patients, who have received\n      bevacizumab treatment before entering the study, will be enrolled in the phase II part. In\n      addition, a surgical arm will start concurrently with the phase II part, to determine the\n      PK/PD profile of the study drug combination in patients undergoing tumor resection for\n      recurrent glioblastoma after 7 to 10-days treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years of age.\n\n          -  Histologically confirmed diagnosis of glioblastoma after initial tumor resection with\n             radiographic evidence of recurrent tumor per RANO criteria.\n\n          -  Documented evidence of PTEN mutations, homozygous deletion of PTEN or PTEN negative\n             by IHC confirmed by local or central assessment\n\n          -  Must have received the following treatment for glioblastoma:\n\n               -  Prior adjuvant treatment with radiotherapy and temozolomide;\n\n               -  A maximum of two prior chemotherapy regimens (including bevacizumab or other\n                  direct VEFG/VEGFR inhibitors)  for recurrent disease are permitted.\n\n          -  Representative archival or newly obtained tumor sample from glioblastoma\n             (formalin-fixed paraffine embedded tissue) must be available.\n\n          -  ECOG performance status \u2265 2.\n\n          -  Able to swallow and retain oral medication.\n\n          -  Patients in the surgical arm only: patients with recurrent glioblastoma must be\n             eligible for surgical resection as deemed by the site Investigator.\n\n        Exclusion Criteria:\n\n          -  Prior or current treatment with a c-MET inhibitor or HGF-targeting therapy\n\n          -  Prior treatment with a PI3K and/or mTOR inhibitors for glioblastoma\n\n          -  Received radiation (including therapeutic radioisotopes such as strontium 89)\n             therapy \u2264 4 weeks prior to the first dose of study treatment and have not recovered\n             from side effects of such therapy (\u2264 Grade 1) prior to the first dose of study\n             treatment, except for alopecia.\n\n          -  Currently being treated with Enzyme Inducing Anti-Epileptic Drug (EIAED). If\n             previously on an EIAED, the patient must be off of it for at least 2 weeks prior to\n             study treatment.\n\n          -  Currently receiving warfarin or other coumadin-derived anticoagulants for treatment,\n             prophylaxis or otherwise.\n\n          -  Currently receiving increasing or chronic treatment ( > 5 days) with corticosteroids\n             or another immunosuppressive agent.\n\n          -  History of acute or chronic pancreatitis or any risk factors that may increase the\n             risk of pancreatitis.\n\n          -  Active cardiac disease or a history of cardiac dysfunction.\n\n          -  Impairment of gastrointestinal (GI) function or GI disease that might significantly\n             alter the absorption of study drug\n\n          -  Medically documented history of or active major depressive episode, bipolar disorder\n             (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal\n             attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or\n             others), or patients with active severe personality disorders (defined according to\n             DSM- IV).\n\n          -  Anxiety \u2265 CTCAE grade 3\n\n          -  Any of the following baseline laboratory values:\n\n               -  Hemoglobin < 9 g/dL\n\n               -  Platelet count  < 75 x 109/L\n\n               -  Absolute neutrophil count (ANC) < 1.0 x 109/L\n\n               -  INR > 1.5\n\n               -  Serum lipase > normal limits for the institution\n\n               -  Asymptomatic serum amylase > grade 2\n\n               -  Potassium, magnesium, and calcium (corrected for albumin) > normal limits for\n                  the institution\n\n               -  Total bilirubin \u22652 x upper limit of normal (ULN)\n\n               -  Serum creatinine >1.5 x ULN or creatinine clearance \u2264 45 mL/min\n\n               -  Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > normal\n                  range (or < 3.0 x ULN if liver metastases are present)\n\n               -  Fasting plasma glucose  > 120mg/dL or > 6.7 mmol/L\n\n               -  HbA1c > 8%."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870726", 
            "org_study_id": "CINC280X2204"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase Ib", 
                    "Phase II"
                ], 
                "description": "INC280 will be given at the starting dose of 200mg twice daily.", 
                "intervention_name": "INC280", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Phase Ib", 
                    "Phase II"
                ], 
                "description": "Buparlisib will be given at the starting dose of 50mg once daily.", 
                "intervention_name": "Buparlisib", 
                "intervention_type": "Drug", 
                "other_name": "BKM120"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "c-MET inhibitor", 
            "PI3K inhibitor", 
            "PTEN mutations", 
            "homozygous deletion of PTEN or PTEN negative by IHC", 
            "INC280", 
            "BKM120", 
            "buparlisib"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "meaghan_elliott@dfci.harvard.edu", 
                    "last_name": "Meaghan Elliott", 
                    "phone": "617-632-2166"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute SC"
                }, 
                "investigator": {
                    "last_name": "Patrick Y. Wen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sm3482@columbia.edu", 
                    "last_name": "Sonia Mendoza", 
                    "phone": "212-305-9858"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center- New York Presbyterian Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Andrew B. Lassman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.carter@duke.edu", 
                    "last_name": "Karen Carter", 
                    "phone": "919-668-0896"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center Duke - Baker"
                }, 
                "investigator": {
                    "last_name": "Annick Desjardins", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jni@mdanderson.org", 
                    "last_name": "Jiyuan Ni", 
                    "phone": "713-745-5769"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center SC-3"
                }, 
                "investigator": {
                    "last_name": "John F DeGroot", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 GD"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "9007"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Netherlands", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Switzerland: Swissmedic", 
                "Germany: German Institute of Medical Documentation and Information", 
                "Netherlands: Medical Ethics Review Committee (METC)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Estimate anti-tumor activity of INC280 in combiation with buparlisib in patients with recurrent glioblastoma.", 
                "measure": "Phase II: Progression free survival rate (PFSR)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of INC280 in combination with buparlisib in patients with recurrent glioblastoma.", 
                "measure": "Phase Ib: Incidence of dose limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Estimate the concentrations of INC280 and buparlisib in tumor tissue.", 
                "measure": "Surgical arm: Concentrations of INC280 and buparlisib in tumor.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870726"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the safety of INC280 in combination with buparlisib.", 
                "measure": "Type, frequency, and severity of adverse events and serious adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "To characterize the tolerability of INC280 in combination with buparlisib.", 
                "measure": "Tolerability: dose interruptions, reductions and dose intensity.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Plasma concentration of INC280 and buparlisib, and PK parameters, including but not limited to Cmax, Tmax, AUCtau, and T1/2.", 
                "measure": "Pharmacokinetic profile of INC280 in combination with buparlisib.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Further assess the anti-tumor activity of INC280 in combination with buparlisib.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "To investigate drug level of INC280 and buparlisib in cerebrospinal fluid (if available).", 
                "measure": "Concentration of INC280 and buparlisib in cerebrospinal fluid (if available).", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Further assess the anti-tumor activity of INC280 in combination with buparlisib.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}